CJC-1295 (No DAC) and Epithalon: What Combination Research Shows
Investigating growth hormone axis modulation alongside telomeric preservation represents an active frontier in cellular longevity and tissue repair assays. This technical overview examines the dual mechanisms of CJC-1295 (No DAC) and Epithalon, evaluating their distinct molecular pathways, current preclinical evidence, assay design parameters, and strict laboratory handling guidelines.
Quick answer
Investigating growth hormone axis modulation alongside telomeric preservation represents an active frontier in cellular longevity and tissue repair assays. This technical overview examines the dual mechanisms of CJC-1295 (No DAC) and Epithalon, evaluating their distinct molecular pathways, current preclinical evidence, assay design parameters, and strict laboratory handling guidelines.
Key takeaways
- In modern biochemical research, scientists frequently design multi-agent in vitro protocols to observe how distinct cellular repair pathways interact.
- [CJC-1295](/research-peptides/cjc-1295-no-dac) (No DAC) is a 29-amino-acid synthetic peptide modified from the natural GHRH molecule at positions 2, 8, 15, and 27.
- [Epithalon](/research-peptides/epithalon) (Epitalon) is a synthetic tetrapeptide with the amino acid sequence L-Ala-L-Glu-L-Asp-Gly.
- When designing protocols involving [cjc-1295](/research-peptides/cjc-1295-no-dac) (no dac) and [epithalon](/research-peptides/epithalon), principal investigators must carefully distinguish between documented empirical co-administration data and theoretical biochemical synergy.
Introduction to Secretagogue and Telomerase Co-Investigation
In modern biochemical research, scientists frequently design multi-agent in vitro protocols to observe how distinct cellular repair pathways interact. Among these pairings, combining growth-hormone-releasing hormone (GHRH) analogs with pineal-derived telomerase activators has drawn considerable interest in the research community. The target compound combination of cjc-1295 (no dac) and epithalon serves as a prime example of this dual-pathway investigative approach.
CJC-1295 (No DAC), also classified in literature as Modified GRF (1-29), operates via signal transduction at the GHRH receptor level. In contrast, Epithalon (a synthetic tetrapeptide) targets pineal gene expression, chromatin structure, and telomerase catalytic activity. Understanding how these two distinct peptide structures function independently and in co-exposure assays provides critical insights into cellular turnover, oxidative stress mitigation, and extracellular matrix preservation.
Molecular Profile and Mechanism of CJC-1295 (No DAC)
CJC-1295 (No DAC) is a 29-amino-acid synthetic peptide modified from the natural GHRH molecule at positions 2, 8, 15, and 27. These amino acid substitutions (D-Ala2, Gln8, Ala15, Lys27) significantly enhance enzymatic stability against dipeptidyl peptidase-IV (DPP-IV) cleavage compared to native GHRH(1-29) amide, while omitting the Drug Affinity Complex (DAC) reactive maleimide group that binds serum albumin.
As a functional GHRH analog, CJC-1295 (No DAC) is studied as a growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. Preclinical studies suggest that by selectively binding to the GHRH receptor on anterior pituitary somatotrophs, the molecule stimulates adenylate cyclase, leading to an intracellular rise in cyclic adenosine monophosphate (cAMP) and pulsatile growth hormone secretion. This dynamic preservation of physiological pulse frequency makes CJC-1295 (No DAC) an essential control and experimental agent in GH axis dynamics.
Molecular Profile and Mechanism of Epithalon
Epithalon (Epitalon) is a synthetic tetrapeptide with the amino acid sequence L-Ala-L-Glu-L-Asp-Gly. Modeled after epithalamin, a natural peptide extract isolated from the bovine pineal gland, Epithalon plays a unique role in cell aging models and epigenetic modulation.
In vitro data indicate that Epithalon induces telomerase activity by promoting the expression of human telomerase reverse transcriptase (hTERT) or its rodent homologs, leading to the elongation of telomeric repeat sequences during mitotic division. Beyond telomere maintenance, preclinical assays demonstrate that Epithalon regulates pineal gland expression, restores nighttime melatonin production in aging animal models, and scavenges reactive oxygen species (ROS) to preserve mitochondrial membrane integrity.
Theoretical Synergy vs. Direct Preclinical Evidence
When designing protocols involving cjc-1295 (no dac) and epithalon, principal investigators must carefully distinguish between documented empirical co-administration data and theoretical biochemical synergy. While both peptides individually target systems associated with somatic integrity and cellular longevity, formal peer-reviewed literature examining their simultaneous co-incubation or combined administration in a single model remains limited.
The theoretical rationale for investigating both compounds in a shared experimental model relies on complementary cellular targets. CJC-1295 (No DAC) drives protein synthesis, nitrogen retention, and IGF-1-mediated signaling downstream of pituitary GHRH activation. Simultaneously, Epithalon acts at the nuclear level to maintain telomere length and regulate circadian transcription factors. While published rodent studies have documented the isolated physiological effects of each agent, researchers studying their combination typically extrapolate from separate baseline assays to observe whether simultaneous stimulation yields additive or permissive biological effects.
Assay Design Considerations in Preclinical Research
Structuring an in vitro or animal model protocol to evaluate cjc-1295 (no dac) and epithalon requires rigorous control parameters to isolate each compound's kinetic contributions. In cell culture models—such as primary dermal fibroblasts, chondrocytes, or isolated somatotrophs—investigators usually establish four distinct experimental cohorts: a negative control group, a CJC-1295 (No DAC) monotherapy group, an Epithalon monotherapy group, and a co-exposure group.
Primary endpoints in these assays typically include Western blot analysis of phosphorylated intracellular signaling proteins (e.g., STAT5, Akt, ERK1/2), fluorometric assays for telomerase activity, RT-qPCR measurements of IGF-1 and TERT mRNA expression, and spectrophotometric quantification of oxidative markers such as malondialdehyde (MDA) and superoxide dismutase (SOD). Establishing baseline sensitivity ranges for each peptide individually is necessary prior to interpreting co-exposure data.
Comparative Class Analysis: Growth Axis and Longevity Peptides
To properly position CJC-1295 (No DAC) and Epithalon within a broader research context, researchers frequently evaluate them alongside other secretagogues and bioregulatory peptides. The growth hormone secretagogue receptor (GHSR-1a) pathway, for example, is distinct from the GHRH pathway activated by CJC-1295 (No DAC).
When designing comparative research panels, investigators frequently examine alternative GHRH and secretagogue formulations alongside bioregulatory peptides. The following matrix illustrates key mechanistic differences across related research compounds available across our catalog of all peptides:
Chemical Stability and Co-Reconstitution Protocols
A critical technical question among laboratory personnel is whether CJC-1295 (No DAC) and Epithalon can or should be combined into a single reconstitution vial. From a strict analytical and physical chemistry standpoint, co-reconstitution of two distinct peptides into a single stock solution is strongly discouraged during controlled laboratory testing.
CJC-1295 (No DAC) and Epithalon possess different isoelectric points (pI), molecular weights (3288.7 g/mol vs. 390.35 g/mol), and pH solubility windows. Mixing lyophilized cakes or concentrated liquid stock in the same container creates risks of peptide-peptide aggregation, altered net charge, and variable adsorption onto container walls. Instead, researchers should reconstitute each lyophilized vial independently using dedicated bacteriostatic water or standard laboratory buffers. Use our interactive reconstitution calculator to determine precise solvent volumes and concentration curves prior to introducing serial dilutions into cell media.
Lyophilized Storage and Handling Requirements
To prevent premature enzymatic degradation, hydrolysis, or oxidation, both CJC-1295 (No DAC) and Epithalon must be handled under standardized cold-chain procedures. Lyophilized peptide cakes should be stored in desiccated freezers maintained at -20°C to -80°C for long-term stability.
Once reconstituted with sterile bacteriostatic water (0.9% benzyl alcohol), liquid aliquots should be refrigerated between 2°C and 8°C and evaluated within a defined assay timeline. Repeated freeze-thaw cycles must be avoided, as the physical shear stress of ice crystal formation can sever peptide backbone bonds and lead to aggregation. Aliquoting working solutions into single-use microcentrifuge tubes immediately following initial dissolution ensures experimental consistency across multi-week studies.
PX1 Research Quality, Purity, and COA Documentation
Rigorous scientific research requires uncompromising chemical purity. Impurities, residual trifluoroacetic acid (TFA), organic solvents, or bacterial endotoxins can confound experimental assays, alter cell viability, and invalidate quantitative data. PX1 Research enforces strict quality standards for all analytical reagents.
Every batch of CJC-1295 (No DAC) and Epithalon synthesized in our USA-based, ISO 17025 accredited and GMP-compliant facilities undergoes high-performance liquid chromatography (HPLC) and mass spectrometry (MS) verification to guarantee purity levels exceeding 99%. Furthermore, every lot is subjected to Chromogenic LAL testing to ensure endotoxin limits remain under 0.01 EU/mg. Institutional accounts and commercial laboratories sourcing through our wholesale program or direct store receive a batch-specific, verifiable COA documenting mass verification, chromatogram profiles, and heavy metal screening.
Frequently Asked Questions
Are CJC-1295 (No DAC) and Epithalon studied together in published human clinical trials?
No. Both compounds are strictly experimental research reagents. There are no FDA-approved human clinical trials or medical protocols establishing combined efficacy or dosing in humans. All data derive from in vitro cell models and animal research.
What is the primary functional difference between CJC-1295 with DAC and CJC-1295 (No DAC)?
CJC-1295 with DAC contains a maleimide group that covalently binds to serum albumin in vivo, extending its biological half-life to several days. CJC-1295 (No DAC), or Mod GRF (1-29), lacks this complex, yielding a shorter biological half-life (~30 minutes) that mimics natural, pulsatile GHRH signaling.
Can CJC-1295 (No DAC) and Epithalon be reconstituted in the same vial for testing?
Co-reconstitution in a single vial is not recommended. Combining distinct peptides in solution can alter solubility profiles, accelerate chemical degradation, or induce peptide aggregation. Each vial should be reconstituted separately before adding to assay media.
What receptor pathways does Epithalon target in preclinical research?
Epithalon acts primarily as a pineal bioregulator. In vitro and animal studies show it stimulates telomerase reverse transcriptase (TERT) expression, regulates pineal gene expression, and aids in restoring endogenous melatonin synthesis.
How does PX1 Research verify the purity and identity of its peptides?
Every lot manufactured in our USA facilities undergoes third-party verification using High-Performance Liquid Chromatography (HPLC) for purity and Mass Spectrometry (MS) for exact molecular weight confirmation. Endotoxin testing is also conducted per lot.
What diluent is recommended for reconstituting lyophilized research peptides?
Sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline (0.9% NaCl) are standard diluents for laboratory reconstitution, depending on the specific requirements of the downstream assay or cell culture protocol.
Where can researchers obtain a batch-specific Certificate of Analysis (COA)?
Batch-specific COAs detailing HPLC purity, mass spectrometry confirmation, and endotoxin assay results are available directly on the PX1 Research COA portal by entering the product lot number.
How should reconstituted peptide solutions be stored between assay runs?
Reconstituted peptide liquids should be kept refrigerated at 2°C to 8°C and protected from light. For extended assay series, working aliquots should be frozen once at -20°C to avoid repeated freeze-thaw cycles.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.